HCW Biologics Inc.
HCWB
$4.10
$0.040.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -63.19% | -9.68% | 22.27% | 2.82% | 7.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -63.19% | -9.68% | 22.27% | 2.82% | 7.68% |
| Cost of Revenue | -60.23% | -29.55% | 3.49% | -11.54% | -2.57% |
| Gross Profit | -70.26% | 71.23% | 96.70% | 60.22% | 43.62% |
| SG&A Expenses | -4.18% | 29.22% | 130.50% | 178.49% | 123.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.78% | 12.21% | 67.34% | 75.84% | 43.11% |
| Operating Income | 6.82% | -14.63% | -73.59% | -90.08% | -50.07% |
| Income Before Tax | 9.63% | -20.12% | -89.19% | -105.09% | -52.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.63% | -20.12% | -89.19% | -105.09% | -52.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.63% | -20.12% | -89.19% | -105.09% | -52.90% |
| EBIT | 6.82% | -14.63% | -73.59% | -90.08% | -50.07% |
| EBITDA | 8.14% | -15.11% | -78.43% | -94.09% | -50.29% |
| EPS Basic | 15.71% | -13.26% | -82.72% | -99.19% | -51.04% |
| Normalized Basic EPS | 10.26% | -12.23% | -74.88% | -90.77% | -49.54% |
| EPS Diluted | 15.71% | -13.26% | -81.15% | -97.09% | -49.38% |
| Normalized Diluted EPS | 10.26% | -12.23% | -74.88% | -90.77% | -49.54% |
| Average Basic Shares Outstanding | 12.11% | 7.97% | 3.68% | 2.43% | 1.16% |
| Average Diluted Shares Outstanding | 12.11% | 7.97% | 3.68% | 2.43% | 1.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |